MedPath

Paraffin Bath Therapy for Chronic Hand Eczema

Not Applicable
Completed
Conditions
Eczema
Interventions
Other: Paraffin baths therapy
Registration Number
NCT04510961
Lead Sponsor
Cairo University
Brief Summary

Objective: Chronic Hand eczema (CHE) is a common inflammatory skin disease has a major medical psychological and socio-economic implications that affect quality of life (QoL)and work ability. This study, the first randomized controlled trial that will be conducted to evaluate the effect of paraffin bath therapy (PBT) in the treatment of CHE.

Detailed Description

Design: The study design is a randomized controlled trial with measures at pre-and post-intervention.

Subjects: Sixty patients with moderate to severe Chronic Hand eczema (CHE) will participate in the study. They will be classified randomly into two groups of equal number; paraffin group and the control group.

Interventions: Paraffin group will receive Paraffin bath therapy for 5 days per week for 12 weeks in addition to routine skin care program while the control group will receive routine skin care program.

Outcome Measures:

Objective SCORing Atopic Dermatitis, subjective item score and dermatology life quality index (DLQI) will be assessed before, at 6th week and at 12th week of treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Age from 20-40 years
  • Time elapsed from the beginning of the disease ; more than three months according to the Guideline of the German Dermatological Society
Exclusion Criteria
  • active eczematous lesions on other parts of the body;
  • malignant or premalignant skin tumors

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Paraffin baths therapy (PBT) :group AParaffin baths therapyPatients in treatment group will receive paraffin wax baths for five days per week for 12 weeks.
Primary Outcome Measures
NameTimeMethod
SCORAD ("SCORing Atopic DermatitisChange from Baseline at SCORAD score at 6th week and at 12th weeks of treatment

is the most widely clinical tool for assessing the severity (i.e. extent, intensity) of atopic dermatitis as objectively as possible.20 It consists of six objective items (erythema, oedema/papules, effect of scratching, oozing/crust formation, lichenification, and dryness), and two subjective symptoms (itch and sleeplessness), the maximum score is 103 points

Secondary Outcome Measures
NameTimeMethod
Dermatology life quality index (DLQI)Change from Baseline at 6th week and at 12th weeks of treatment

DLQI consists of ten questions describe symptoms, feelings, leisure activities, work or school activities, personal relationships and treatment

Trial Locations

Locations (1)

Zizi Mohammed Ibrahim Ali

🇸🇦

Riyadh, Saudi Arabia

© Copyright 2025. All Rights Reserved by MedPath